Summary Twenty-four assessable patients with hormone-resistant prostate cancer (HRPC) were to receive daily doses of oral estramustine phosphate (EMP), 10 mg kg-1, and intravenous epirubicin (EPR) infusions, 100 mg m-2, every third week up to a cumulative dose of 500 mg m-2. Biochemical response [. 50% reduction in pretreatment serum prostate-specific antigen (PSA) after three cycles of 2 3 weeks' duration] was demonstrated in 13 of 24 patients included (54%). No objective response (WHO criteria) was observed, although seven of nine evaluable patients achieved a . 50% serum PSA reduction. Subjective improvement (pain score, performance status) occurred in 7 of 24 patients, whereas nine patients progressed subjectively. There was no correlation between subjective and biochemical response.
Metastatic prostate cancer progressing during androgen-suppressive treatment represents a therapeutic dilemma. No consensus exists on the optimum medical treatment of this condition, which conventionally comprises progressive disease in spite of castration levels of serum testosterone. The median survival of symptomatic patients with hormone-resistant prostate cancer (HRPC) is 8-10 months (Foss'a et al, 1992a; Newling et al, 1993) . Androgen independence most probably reflects the selection of hormoneresistant cell clones.
The lack of objective assessable response parameters has been the major obstacle to the development of new treatment modalities in HRPC. Sclerotic bone metastases, increased uptake on bone scans and the primary tumour are all unsuitable measures of treatment response (Jones et al, 1986; Smith et al, 1990) , and patients with bidimensionally measurable metastatic lesions represent a minority. Furthermore, it has been claimed that the tumour biology of these patients may differ from that in patients with skeletal metastases. After the introduction of prostate-specific antigen (PSA) in the management of previously untreated prostate cancer, this tumour marker has increasingly been used in patients with HRPC. However, the clinical role of PSA in HRPC may differ from that in patients before and during primary hormone treatment.
Estramustine phosphate (EMP) has been used in the treatment of prostate cancer for many years. This nomitrogen mustard carbamate derivative of oestradiol-1713 phosphate displays both oestro-genic and cytotoxic activities without leading to bone marrow suppression. In vitro EMP inhibits polymerization of microtubules by interaction with tubulin-binding domains of microtubuleassociated proteins (MAPs), thereby inhibiting the cytoskeletal networks contributing to cell motility and cell division (Steams et al, 1988; Dahll0f et al, 1993) . Promising results have recently been reported for the use of EMP combined with etoposide or vinblastine in the treatment of HRPC (Hudes et al, 1992; Seidman et al, 1992; Pienta et al, 1994) .
Epirubicin (EPR) , the 4' epimer of doxorubicin, is an anthracycline derivative. EPR and doxorubicin have shown some efficacy in the treatment of HRPC, both as single drug treatment and, considering doxorubicin, as a part of combination treatment.
Based on the efficacy and tolerability of EMP and EPR even in patients of high age and with limited haematopoietic reserves, it was reasonable to combine the two agents in the treatment of patients with HRPC. In the present study we deal with the results of a phase II study evaluating the combination of EPR and EMP in HRPC. dose reduction of 25%. EPR was combined with daily oral EMP at a dose of 10 mg kg-', given in two doses per day. Patients were instructed to avoid milk and milk products during EMP treatment. Furthermore, the capsules should be taken at least I h before or 2 h after meals (Gunnarsson et al, 1990) . The end of the trial was defined as the achievement of the maximal accumulated EPR dose (500 mg m-2) or the development of intolerable toxicity and/or objective or subjective progression (see below). Biochemical progression (see below) did not represent the course of trial discontinuation. Treatment after discontinuation of the trial drugs was up to the clinician's discretion with the recommendation to continue single-drug EMP therapy.
PATIENTS AND METHODS Patients

Pretreatment and follow-up examinations
At trial inclusion ECG and chest radiography were performed together with a radioisotope bone scan, which enabled categorization of the extent of disease (EOD) according to Soloway et al (1988) (EOD grade 0-4). The clinical examination included assessment of body weight, performance status and pain score (analgesics not required = 0, non-narcotics occasionally required = 1, non-narcotics regularly required = 2, narcotics occasionally required = 3, narcotics regularly required = 4). In 12 patients with objectively measurable soft-tissue lesions these were evaluated by clinical or radiological assessments. All patients underwent haematological tests [haemoglobin (Hb) , WBC and platelet counts] together with liver and kidney function tests, determination of serum PSA and serum testosterone. Serum PSA was measured by an in-house immunofluorometric assay using two monoclonal antibodies and delayed fluorescence immunoassay technique. The assay is run on a Wallac 1235
AutoDelfia analyser, has a sensitivity better than 0.1 gg 1-', and a between-assay coefficient of variation below 5%. The assay was standardized against Hybritec Tandem-R (Wahre et al, 1992) .
Regular follow-up examinations were performed 3 weeks after each EPR infusion and every sixth week after discontinuation of EPR, or until the development of objective or subjective progression (see below). Thereafter, patients went off-study, followed up by general practitioners or local hospitals. Progress forms were sent to the Norwegian Radium Hospital. At each regular follow-up the clinical examination and haematological and biochemical tests were repeated. The haematological status was also controlled on day 8 and 15 of each cycle. Radiological or clinical measurements of soft-tissue metastases were repeated after three cycles of treatment. The ECG was repeated if clinically indicated. 'Median; 2range. and a platelet count > 100 x 109 1-1 were included. Other major eligibility criteria were performance status < grade 2 (WHO criteria), no major cardiovascular dysfunction assumed to preclude the use of the trial drugs, no previous systemic chemotherapy and the patient's written and verbal informed consent. The protocol was approved by the Regional Ethical Committee of Health Region II, Norway.
Therapeutic regimen
Epirubicin was administered intravenously in a slowly running saline drip at a dose of 100 mg m-2 every third week. If the WBC count was < 3.0 x 109 1-1 on day 22 of a cycle and/or the platelet count < 100 x 109 1-', EPR was delayed for 1 week with subsequent
Response evaluation
The main outcome parameter was biochemical response assessed by . 50% reduction of the pretreatment serum PSA level after at least three cycles and lasting for at least 3 weeks. Biochemical progression was defined as increase in the nadir serum PSA level of . 50%, the serum PSA level at progression being at least 20 gg 1-'. After the completion of three cycles, objective response was evaluated according to the WHO criteria (Miller et al, 1981) . Beneficial subjective response (improvement) required the reduction of the pain score by at least one score and/or improved performance status by at least one score without being induced by other palliative measures. The scores of performance status 0 and 1 were combined when evaluating subjective response, disregarding changes between these two categories. Subjective progression (deterioration) comprised increase of the respective scores by > 1. (Figure 2A and B) . No complete or partial response was observed in the nine evaluable patients with soft tissue metastases. In seven of these nine patients, the pretreatment serum PSA declined by at least 50%. Seven patients experienced subjective improvement At the end of the observation time two patients were dead of prostate cancer. The overall survival rate after 6 months' observation time was 96%.
Toxicity
Eighteen of the 92 cycles of EPR were associated with the occurrence of grade 3/4 leucopenia (eight patients), and 6 cycles with grade 3/4 thrombocytopenia (two patients) ( (1997) 76(1) (Eisenberger et al, 1985) . As in the present study, some agents or drug combinations have shown promising activity in phase II studies, but without lifeprolonging effect of treatment. The results from such trials should be transferred to routine practice with caution. Furthermore, there may be differences between the experience in America and Europe, and between medical oncologists and urologists. American trial patients with HRPC are often positively selected younger individuals with little or no pain, a good performance status, adequate bone marrow and kidney function and limited tumour volume. The majority of HRPC patients seen in routine urological practice in Europe, however, suffer from severe metastatic bone pain, display a decreased general condition and co-morbidity and have often reduced bone marrow function due to high age and metastatic involvement. These general limitations and selection bias are also valid for the present study. Of the 24 patients included, 21 had performance status 0/1 and ten patients did not use any analgesics despite progressive metastatic prostate cancer. In comparison, in a joint study from the Royal Marsden Hospital, London, and the Norwegian Radium Hospital, Oslo, among patients with HRPC referred for palliative treatment only 40% displayed a performance status of 0/1 and pain was a clinical problem in 78% of them (Foss'a et al, 1992a) . Furthermore, half of all patients in the present study presented metastatic soft-tissue lesions, whereas such metastatic involvement is usually present in only 10-15% of patients with advanced prostatic cancer. The positive selection of our patients also becomes evident by the favourable 6-month survival of 96%, whereas the comparable percentage of untreated patients referred for palliative radiotherapy of skeletal metastases was 60% (Foss'a et al, 1992a) . When evaluating trial results it is important to take into account such selection biases as they may mirror different tumour biology in trial patients compared with non-trial patients.
The extended use of PSA as a serum tumour marker in diagnosis and during follow-up of prostate cancer has led to the increasing application of this tumour marker during the management of HRPC. As in the present study, a . 50% reduction in pretreatment serum PSA has been the primary objective of many trials (Table 6 ) (Hudes et al, 1992; Seidman et al, 1992; van Rijswijk et al, 1992; Yagoda et al, 1993; Foss'a et al, 1994; Pienta et al, 1994; Brausi et al, 1995; Eisenberger at al, 1995) . The significance of serum PSA as a tumour marker for prognosis and tumour response in HRPC may, however, be questioned. Foss'a et al (1992c) was not able to establish the prognostic significance of different serum PSA levels in patients with symptomatic HRPC. In the present study no correlation was detected between biochemical and objective response, as also observed by other authors (Seidman et al, 1992; Yagoda et al, 1993) . Admittedly only nine patients were evaluable. These clinical data are consistent with in vitro observations: PSA production and secretion are androgen dependent, and androgen deprivation may lead to decrease of PSA production without corresponding cell death (Csapo et al, 1988; Rocca et al, 1991; Gleave et al, 1993) . Despite the lack of relationship between biochemical and objective response in our and other studies, a relation between treatment-associated PSA reduction and favourable survival in patients with HRPC has been demonstrated (Kelly et al, 1993; Thibault et al, 1993) . This can, however, be explained by the possibility that PSA reduction is most often obtained in patients with a biologically less aggressive disease and favourable survival rates independent of the PSA decrease. Further large clinical studies are needed to evaluate the role of PSA and its components (free vs bound PSA) as a tumour marker in HRPC. In addition, PSA reductions should be related to known pretreatment parameters (such as performance status, alkaline phosphatase, lactate dehydrogenase, haemoglobin, duration of hormone dependency; Foss'a et al, 1992b) in order to establish the independent significance of PSA reduction.
EMP is usually categorized as a cytotoxic agent with no or limited myelotoxicity. Dependent on selection criteria of the patients and the definition of response criteria, EMP has shown variable response rates (Benson et al, 1986) . In the clinical situation it has been difficult to prove the cytotoxic effect of single-drug EMP therapy (Newling et al, 1993; Fossa et al, 1990) , whereas the British Joumal of Cancer (1997) 76(1), [93] [94] [95] [96] [97] [98] [99] results of recent trials combining EMP with etoposide and vinblastine are more promising (Hudes et al, 1992; Seidnian et al, 1992; Pienta et al, 1994) . The concomitant use of EPR precludes any statement about EMP-induced bone marrow suppression in our trial. The previously described oestrogenic effect of EMP (Benson et al, 1990 ) also became evident in the present study, in which 12 patients developed gynaecomastia, five of them with painful breast enlargement. Based on clinical observations one has to consider the possibility that high-dose EMP, as used in the present study, may display its main activity by high oestrogen levels. High-dose oestrogen treatment is a therapeutic modality known to be effective in prostate cancer patients progressing after primary androgen-suppressive treatment (Smith et al, 1986; PavoneMacaluso et al, 1986) . Many of these patients, including some from the present study, may virtually still be hormone dependent though androgen independent.
EPR in a low-dose regimen has been explored by several investigators. The EORTC Genitourinary Group (protocol 30841) used EPR 12 mg m-2 weekly with an objective response rate (complete or partial) of only 12% (Jones et al, 1987) . Francini et al (1993) presented a 37.7% response rate (bone scan, soft-tissue metastases, acid phosphatase, weight, symptoms and performance status) after EPR 30 mg m-2 weekly, and Elomaa et al (1991) demonstrated improved performance status in 69% of patients using EPR at 25 mg m-2 weekly. In order to increase efficacy, but still within a level of tolerable toxicity, higher doses of EPR have been tested. Brausi et al (1995) , tested EPR 100 mg m-2 intravenously every 3 weeks, with the results of 24% partial response and 42% stable disease according to WHO criteria. The same dosage schedule was employed in the present study and found to be tolerable in the majority of trial patients. However, a further increase in dose in future EPR combination regimens is not recommended. Reductions of single doses may, on the contrary, be preferable in clinical use, allowing prolonged periods of treatment before reaching the maximal cumulative dose of 500 mg m-2.
The haematological toxicity was unpredictable, but generally within acceptable levels. However, as many as eight patients developed grade 3/4 leucopenia, one patient requiring hospitalization. The non-haematological side-effects were generally well tolerated and not dose related. Four patients presented symptoms of cardiovascular toxicity; in three patients their condition required hospitalization. 'Chills', as experienced by five of our patients, should be viewed on the background of previously reported temperature rise associated with high-dose EPR (Ganzina et al, 1983; Martoni et al, 1990; Brausi et al, 1995) . Although the development of angioedema in one of two patients was related in time to EPR infusions, it was most probably related to the use of EMP. Pienta et al (1994) reported allergic reactions with rash and tongue swelling in three patients during combined EMP (15 mg kg') and etoposide therapy. The occurrence of angioedema during EMP treatment may be related to the high doses of this drug and/or associated with the simultaneous use of other drugs which increase the risk of this side-effect, for instance ACE inhibitors (Hedner et al, 1992) .
In this limited series of patients with HRPC the combination of high-dose EPR and EMP appears to be effective in achieving serum PSA reduction by > 50%. The treatment is generally well tolerated, but grade 3/4 bone marrow depression may occur. The risk of angioedema should not be overlooked when using highdose EMP in patients with HRPC. Our results warrant further exploration of the clinical significance of PSA changes during the treatment of patients with HRPC.
